NCI launches research network to evaluate emerging cancer screening technologies

University of Cincinnati receives $2.3M from NCI to visualize CAR T cells within the body

The University of Cincinnati Cancer Center was granted $2.3 million from NCI to develop a technique to visualize where genetically modified immune cells go in the body after being administered to patients with cancer.

November 22, 2024

Vol.50 No.44

White House

As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer

President-elect Donald Trump said he would nominate Robert F. Kennedy Jr. to the post of secretary of the Department of Health and Human Services, placing the vaccine skeptic in charge of a vast empire of research, engineering, regulatory, and health care agencies.

NCI renews IU Simon Comprehensive Cancer Center’s designation

NCI renewed the Comprehensive Cancer Center designation to the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, awarding it a five-year, $14.2 million grant.

November 15, 2024

Vol.50 No.43

Drugs & Targets

Mainz Biomed and Thermo Fisher collaborate to develop next-gen global CRC screening product

Mainz Biomed, a molecular genetics diagnostic company specializing in the early detection of cancer, announced a collaborative agreement with Thermo Fisher Scientific Inc. through its subsidiary Life Technologies Corporation.

November 15, 2024

Vol.50 No.43

Clinical Trials & Tribulations

A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

In this week’s issue of JAMA Oncology, there is an important paper that provides information concerning the long-term adverse effects and complications of prostate cancer screening and treatment. xxx:more

Long-term risks from prostate cancer treatment detailed in new report

A new report says those considering PSA screening need such quantitative information on risks and benefits of treatment if they are to make truly informed decisions. Yet leading guidelines do not provide specific estimates of risk. The risks of adverse effects and complications from treatment for prostate cancer are substantial and continue for years after...

November 08, 2024

Vol.50 No.42

NCI launches research network to evaluate emerging cancer screening technologies

YOU MAY BE INTERESTED IN

University of Cincinnati receives $2.3M from NCI to visualize CAR T cells within the body

As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer

NCI renews IU Simon Comprehensive Cancer Center’s designation

Mainz Biomed and Thermo Fisher collaborate to develop next-gen global CRC screening product

A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

Long-term risks from prostate cancer treatment detailed in new report

Renew today!

Subscriber content

Never miss an issue!

Login

NCI launches research network to evaluate emerging cancer screening technologies

YOU MAY BE INTERESTED IN

University of Cincinnati receives $2.3M from NCI to visualize CAR T cells within the body

As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer

NCI renews IU Simon Comprehensive Cancer Center’s designation

Mainz Biomed and Thermo Fisher collaborate to develop next-gen global CRC screening product

A study measures the long-term downside of prostate cancer screeningA paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

Long-term risks from prostate cancer treatment detailed in new report

Never miss an issue!

Login

A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment